{"id":829693,"date":"2025-03-25T16:33:35","date_gmt":"2025-03-25T20:33:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/"},"modified":"2025-03-25T16:33:35","modified_gmt":"2025-03-25T20:33:35","slug":"affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/","title":{"rendered":"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MANNHEIM, Germany, March  25, 2025  (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois.<\/p>\n<p align=\"justify\">Details of the poster presentation are as follows:<\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced\/Metastatic Non-Small Cell Lung Cancer<\/p>\n<p>\n        <strong>Authors:<\/strong>\u00a0Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Sch\u00fctz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko<\/p>\n<p>\n        <strong>Session Category and Title:<\/strong> Phase II Clinical Trials 1<\/p>\n<p>\n        <strong>Session Date and Time:<\/strong>\u00a0Tuesday, April 29, 2025, 9:00 AM \u2013 12:00 PM CDT<\/p>\n<p>\n        <strong>Location:<\/strong>\u00a0Poster Section 49<\/p>\n<p>\n        <strong>Poster Board Number:<\/strong>\u00a01<\/p>\n<p>\n        <strong>Published Abstract Number:<\/strong>\u00a0CT161<\/p>\n<p align=\"justify\">The full abstract will be published online on April 25, 2025.<\/p>\n<p align=\"justify\">More details about the programs for the AACR Annual Meeting 2025 are available online at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MCY_5HC1aJ-JGdtCV3XC77AfQECeWvfQtwVswsxx0uh5Br8nkHXb3KvrF7Ef4a0KPQqRmFc5rRIoA3JI6K0BAa2o1r-vAbDXizlQygbU4sz-VsZ5KoN1nZmwFRQ4PEKX1gS2FFMEpy14ri2Z0fw3HNYoi8BdtWOXWSmmm0zB5M1c4aejHCi4Ept5XMOLEA8T\" rel=\"nofollow\" target=\"_blank\">AACR Annual Meeting 2025 | Meetings | AACR<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About AFM24<\/strong><br \/>\n        <br \/>AFM24 is a tetravalent, bispecific ICE<sup>\u00ae<\/sup> that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed\u2019s fit-for-purpose ROCK<sup>\u00ae<\/sup> platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.<\/p>\n<p>\n        <strong>About Affimed N.V.<\/strong>\n      <\/p>\n<p align=\"justify\">Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company\u2019s innate cell engagers (ICE<sup>\u00ae<\/sup>) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE<sup>\u00ae<\/sup> are generated on the Company\u2019s proprietary ROCK<sup>\u00ae<\/sup> platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells.\u00a0 A number of ICE<sup>\u00ae<\/sup> molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients\u2019 lives. For more about the Company\u2019s people, pipeline and partners, please visit: www.affimed.com.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Alexander Fudukidis<br \/>Director, Investor Relations<br \/>E-Mail: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4hfhgzW4i5pGcY_Gx-67rCgUypQ0hyjfkrYKZcXpj6A35bQHRsKiGiMpveUwapnGrgXH-HBWegEmpgmD5tvsjse1mrwhcW3uzEGnNVENoeai44XSPblC5H6XIytNc-nI\" rel=\"nofollow\" target=\"_blank\">a.fudukidis@affimed.com<\/a><\/u><br \/>Tel.: +1 (917) 436-8102<\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Mary Beth Sandin <br \/>Vice President, Marketing and Communications<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7pnoPO9oZfz6G0h199e2RHCyeitvsg9Ss_IQJ1vNgfO66NJSm9SPrAcge3nQfhA8L4VEGH9iv2XvbXEhthd9Rjg01LPUEiloNbAyFjQcA7Y=\" rel=\"nofollow\" target=\"_blank\"><u>m.sandin@affimed.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjdkYjUxYzQtYWJlZS00MTBmLWE2N2QtMmNjZmE1ZWVkMjQ3LTEwMTUzMDctMjAyNS0wMy0yNS1lbg==\/tiny\/Affimed-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois. Details of the poster presentation are as follows: Title:\u00a0Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced\/Metastatic Non-Small Cell Lung Cancer Authors:\u00a0Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Sch\u00fctz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko Session Category and Title: Phase II &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829693","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois. Details of the poster presentation are as follows: Title:\u00a0Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced\/Metastatic Non-Small Cell Lung Cancer Authors:\u00a0Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Sch\u00fctz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko Session Category and Title: Phase II &hellip; Continue reading &quot;Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T20:33:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting\",\"datePublished\":\"2025-03-25T20:33:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/\"},\"wordCount\":437,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/\",\"name\":\"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=\",\"datePublished\":\"2025-03-25T20:33:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - Market Newsdesk","og_description":"MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois. Details of the poster presentation are as follows: Title:\u00a0Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced\/Metastatic Non-Small Cell Lung Cancer Authors:\u00a0Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Sch\u00fctz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko Session Category and Title: Phase II &hellip; Continue reading \"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T20:33:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting","datePublished":"2025-03-25T20:33:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/"},"wordCount":437,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/","name":"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=","datePublished":"2025-03-25T20:33:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTgwOSM2ODMxMjc2IzIwMDM3MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-presentation-at-american-association-for-cancer-research-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829693"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}